Knight Therapeutics (TSE:GUD) Shares Down 0.6%

Share on StockTwits

Shares of Knight Therapeutics Inc. (TSE:GUD) traded down 0.6% during trading on Monday . The stock traded as low as C$5.22 and last traded at C$5.23. 345,502 shares changed hands during trading, a decline of 4% from the average session volume of 359,343 shares. The stock had previously closed at C$5.26.

Several analysts recently commented on the stock. National Bank Financial restated an “outperform market weight” rating on shares of Knight Therapeutics in a report on Thursday, March 25th. Raymond James restated an “outperform” rating and set a C$8.00 price target on shares of Knight Therapeutics in a report on Friday, March 26th. Finally, Bloom Burton upgraded shares of Knight Therapeutics from an “accumulate” rating to a “buy” rating in a report on Friday, March 26th.

The stock has a market cap of C$673.44 million and a P/E ratio of 16.39. The firm’s 50-day moving average is C$5.27 and its two-hundred day moving average is C$5.41. The company has a quick ratio of 4.23, a current ratio of 4.84 and a debt-to-equity ratio of 6.34.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, March 25th. The company reported C$0.03 earnings per share for the quarter, beating the consensus estimate of C$0.01 by C$0.02. The business had revenue of C$55.19 million for the quarter, compared to the consensus estimate of C$47.00 million. Analysts anticipate that Knight Therapeutics Inc. will post 0.04 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile (TSE:GUD)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer.

Recommended Story: Accumulation/Distribution

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.